To the Editor.
—Dr Dong and colleagues,1 obviously trusting and competent scientists, learned the hard way of the need for a consultation when dealing in a different area, ie, the law. It should be universal academic policy that either the institution's or the investigator's lawyer should review any contract before signing. It is the same lesson other colleagues learned the hard way about "hold harmless" clauses.Rather than fear lack of funding from some companies, reputable businesses would welcome work done at institutions of impeccable integrity. As former medical director of a large skin-care company, I was responsible for product safety. If there was a problem with a product, we wanted to know immediately so that (1) it could be corrected, and (2) when claims were made, the industry and the public knew the products were reliable. This is smart business. Suppressing negative information for deceptive profit is, in the xlong run
Gordon BD. Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising. JAMA. 1997;278(11):896. doi:10.1001/jama.1997.03550110034019
Customize your JAMA Network experience by selecting one or more topics from the list below.